Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKG:9989)

Hong Kong · Delayed Price · Currency is HKD

3.915

+0.015 (0.38%)

Oct 28, 2026, 9:35 AM HKT

Market Cap	14.21B -18.3%
Revenue (ttm)	6.05B -0.4%
Net Income	234.27M -49.9%
EPS	0.16 -49.9%
Shares Out	n/a
PE Ratio	24.06
Forward PE	n/a
Dividend	0.17 (4.24%)
Ex-Dividend Date	May 27, 2026

Volume	44,000
Open	3.870
Previous Close	3.900
Day's Range	3.870 - 3.915
52-Week Range	3.740 - 5.770
Beta	0.28
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About HKG:9989

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1998

Employees 2,150

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 9989

Financial Performance

In 2025, HKG:9989's revenue was 5.48 billion, an increase of 3.75% compared to the previous year's 5.28 billion. Earnings were 349.49 million, a decrease of -45.96%.

Financial numbers in CNY Financial Statements